alpha 1H

DRUG2 trials

Sponsors

Hamlet BioPharma AB

Conditions

Non-Muscle Invasive Papillary Bladder CancerNon-muscle invasive bladder cancer awaiting transurethral surgery

Phase 1

A Randomized Placebo controlled Phase I/II Study Evaluating the Safety and Efficacy of Alpha1H in adult patients with non-muscle invasive bladder cancer awaiting transurethral surgery

CompletedCTIS2024-514628-17-00

Hamlet BioPharma ABNon-muscle invasive bladder cancer awaiting transurethral surgery

Start: 2018-05-21End: 2025-04-30Target: 76Updated: 2025-01-09

Phase 3

A Randomized Phase III Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants with Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer

Not yet recruitingCTIS2026-525531-16-00

Hamlet BioPharma ABNon-Muscle Invasive Papillary Bladder Cancer

Target: 169Updated: 2026-06-29